Aurobindo Pharma, Sandoz Terminate U.S. Dermatology, Oral Solid Businesses Deal
Aurobindo Pharma Ltd. said it reached a mutual agreement with Sandoz Inc. to terminate the deal to acquire the Novartis AG subsidiary's generic oral solids and dermatology businesses in the U.S.
The decision was taken as the companies did not get the U.S. Federal Trade Commission's approval within anticipated timelines, the Hyderabad-based company said in an exchange filing. In February, the company in its October-December quarter earnings conference call had said that they expected the deal closure in a few weeks.
Aurobindo Pharma had entered into an agreement to acquire Sandoz's commercial operations and three manufacturing facilities in the U.S. for $900 million in September 2018. The acquisition was proposed to be done in an all-cash basis, without taking in any cash or debt from the acquired business. The deal terms also envisaged additional potential earn-outs for Aurobindo Pharma in the outer years. The deal was to be funded via debt, as per the company.
Analysts' View
The deal termination will impact Aurobindo Pharma's near-term earnings per share, Vishal Manchanda, pharma analyst at Nirmal Bang Institutional Equities, told BloombergQuint on the phone. The upside is that the balance sheet will remain lean, as external debt would have been needed to complete the acquisition, he added. Aurobindo Pharma had Rs 6,077 crore debt and Rs 2,134 crore cash on books, as per its balance sheet at the end of the September quarter.
The deal was critical for Aurobindo Pharma as it is currently very U.S. dependent, and its termination could lead to a derating, Param Desai, pharma analyst at Elara Capital, told BloombergQuint. Leverage not rising is a positive, according to Desai, but he expects the stock to react negatively on Friday.
Despite a 33 percent recovery in March, the stock is still 35 percent lower than the high it hit in February. Aurobindo Pharma is currently the cheapest large-cap pharma stock, trading at a valuation of 7 times its current year price-to-earnings multiple. 29 of the 36 analysts tracking the stock have a buy recommendation, but that was factoring in the Sandoz deal.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.